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Psychologic Stress and
Asthma: Neuropeptide
Involvement 
In a recent Grand Rounds in Environmental
Medicine article, Wright and Steinbach (1)
highlighted the influence of psychosocial
stress on asthmatic attacks. The reported
case histories support basic neuroimmuno-
logic studies, which document modulation
of immune reactivities by psychologic stress,
and the need to consider psychologic stress
along with environmental chemical and
physical stresses, which alone or in combina-
tion can alter physiologic homeostasis result-
ing in ill health (2,3). With the four case his-
tories described by Wright and Steinbach
(1), the influence of emotional factors is
brought into context with physiologic dis-
turbances, and the reference to violence as
“an unrecognized environmental exposure”
emphasizes the need to make more
researchers aware of the impact that psycho-
logic status can have on neuroimmune inter-
actions and health (4). Wright and
Steinbach (1) stated that their report was
“... to alert clinicians and researchers to a
potential risk factor [psychologic stress] for
increased asthma morbidity that has not pre-
viously been recognized.” However, it has
been known for more than a century that
cognitive neural circuits can alter immune
responsiveness. In 1886, a New England
physician demonstrated that individuals
with an allergy to roses could have an aller-
gic response triggered by the perceived pres-
ence of the allergen, an artificial rose (5).
Thus, allergic responses can be elicited in
the absence of allergen, and asthma has
been reported to occur with emotional
changes (6). Although it may be argued
that not all asthmatic episodes are allergic
or even immunologically driven, there is
substantial evidence connecting immune
responses and asthma, and it is well docu-
mented that the nervous system can regu-
late immune functions. More specifically, it
has been suggested that neural control of
airways is involved in the pathogenesis of
asthma (7), but the mechanistic connec-
tions have not been confirmed (8,9). As
referenced by Wright and Steinbach (1),
central nervous system involvement in asth-
ma is related to environmental stresses that
can occur from psychologic disturbances.
Although, to date, the involvement of spe-
cific neurotransmitters or neuropeptides
has not been fully delineated in asthmatic
processes, neuropeptides from C-fibers of
the sensory (sympathetic) nervous system,
which innervate the lungs as well as other
organs (10), are known to have multiple
effects on immune reactivities. 
Vasoactive intestinal peptide increases
mast cell trafficking (11); nerve growth fac-
tor (NGF) and substance P influence mast
cell development and degranulation
(12–14); and histamine from mast cells is
known to induce asthmatic responses.
Another cell associated with asthma is the
eosinophil; calcitonin gene-related peptide,
substance P, and vasoactive intestinal pep-
tide enhance eosinophil chemotaxis (15,16).
Neuropeptides also can modulate IgE syn-
thesis, which is implicated in allergic asthma
(17). Interestingly, in a report by Larsen et
al. (18), a mouse strain that produced an
IgE response to aerosolized ovalbumin
(BALB/c mice) had an enhanced airway
response to electrical field stimulation, but a
strain that produced mainly IgG did not
show an enhanced response. The enhanced
BALB/c response could be transferred to a
nonimmunized syngeneic mouse by peri-
bronchial lymph node cells; the authors
suggested that the lymph node cells from
sensitized BALB/c mice altered neural con-
trol of airways (18). Further complexities of
neuroendocrine immune circuit involve-
ment in airway physiology/pathology, as
well as other immune-associated patholo-
gies, have been documented with produc-
tion of regulatory neuropeptides by lym-
phocytes and macrophages (19–23) and
immune cytokine alteration of neuropep-
tide production (24,25). A posited link
between allergies and depression also has
been suggested (26). In addition, psycho-
logic influences on lymphocyte proliferation
(27) and multiple other immune parameters
(4), including lung infection (28), have
been reported. 
More to the point of the psychologic
impact on asthma, neuropeptides, which
can be immunomodulatory, are released by
emotional stress. The influence of psycho-
logic stress on asthma was the topic of a
workshop sponsored by the National
Institutes of Health (NIH) (29). Research
regarding neural control of airways has
been recommended by the NIH and the
World Health Organization to be an area
that requires further research (30). Exercise
(31) and hyperventilation from physical or
emotional stresses (32) can initiate an asth-
matic attack. Analyses of childhood asthma
have shown substantial interfacing between
the biology of asthma, behavior, stress, and
immune reactivities (33). Psychologic stress
increases NGF production as well as recep-
tors for NGF on lymphocytes (34,35).
NGF release is especially problematic for
asthmatic patients because, in addition to
its effects on mast cells, NGF is known to
cause negative regulation of glucocorticoid
receptors (36), and inhaled glucocorticoid
is a major therapy for asthma. The various
cell types, neuropeptides, and immune fac-
tors involved in asthma are pieces to the
puzzle, but these interconnecting pieces
need to be mechanistically associated before
the mysterious rise in asthma incidence can
be further understood. 
The types of interorgan regulatory con-
trols (e.g., between the endocrine, immune,
and nervous systems exemplified by the
reported violence and asthma associations)
indicate the need for multidisciplinary
approaches to disease analyses. It is often
necessary to take a reductionistic approach
in order to focus on the mechanisms of a
single cell type. The complextities of any
one system demand substantial attention.
However, no one organ system functions
independently of other organ systems. Just
as psychologic, chemical, and physical
stresses can team to alter health, teams of
researchers with different experiences will
be needed to unravel the multidirectional
pathways controlling responses to environ-
mental factors. Psychoneuroimmunology
research has been ongoing for almost a
quarter of a century, and most mechanisms
remain elusive. Toxicant effects on the neu-
roendocrine immune circuitry (neuroim-
munotoxicology research) is even less far
along (37), but researchers need to consider
the psychologic stress on their animals
when evaluating the mechanisms associated
with their favorite toxicant. Lack of appre-
ciation for psychologic effects may increase
the variances within results, which could
especially be important for therapeutic
drug trials. 
The potential involvement of psycho-
logic stress (one form being violence) on
asthma has not actually been unrecog-
nized; it is a research area that has been
neglected.
David A. Lawrence 
Wadsworth Center 
Albany, New York 
E-mail: david.lawrence@wadsworth.org 
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Psychologic Stress and
Asthma: Wright’s Response 
The overall aim of our recent Grand Rounds
in Environmental Medicine article (1) was
to alert clinicians and researchers to exposure
to violence specifically (not stress) as a largely
unrecognized risk factor contributing to
asthma morbidity. This is certainly true in
the arena of clinical medicine. Moreover,
research on the health effects of violence
has typically centered on direct exposure of
individuals to violent acts (2–4). More
recently, investigators have focused on large
population studies to explore the effect on
health outcomes of living in a violent envi-
ronment, with a chronic pervasive atmos-
phere of fear and the perceived threat of
violence (5–7). A growing body of research
has explored potential adverse psychologic
consequences on children growing up in
chronically violent neighborhoods and
homes (8,9). Notably missing, however, are
population-based studies that examine pos-
sible adverse implications that growing up
in a violent environment may have on
physical health, and specifically on chronic
disease expression. 
In our paper (1), we also discussed mul-
tiple plausible pathways through which liv-
ing in a violent environment may influence
asthma expression, including stress; health
behaviors and psychologic factors; access to
health care; and potentiation of an individ-
ual’s response to other environmental expo-
sures (e.g., viruses, allergens). We concur
with Lawrence that increased understanding
of the complex cellular and molecular basis
of airway obstruction and airway inflamma-
tion (10)—in parallel with evidence of
important interactions among behavioral,
neural, endocrine, and immune processes—
provides fresh insight into means by which
psychosocial stress may influence the devel-
opment and expression of asthma (11). The
evidence cited by Lawrence only serves to
further support our argument that experi-
enced stress may be one mechanism
through which exposure to violence is oper-
ating. It is also important to consider how
violence in communities might contribute
to the paradox of deficient asthma care
among people who live almost literally in
the shadows of leading urban medical cen-
ters. Community-based barriers such as
high violence or crime rates may result in
more limited access to pharmacies for need-
ed prescriptions or in the diversion of fund-
ing away from asthma care facilities (1).
Our paper (1) emphasizes the complex
nature of possible interrelationships between
violence and asthma morbidity, drawing on
significant insights from many disciplines
(i.e., sociology, psychology, epidemiology,
trauma, geography, psychoneuroimmunolo-
gy). Given the complex nature of the inter-
relationships between violence (at both the
individual and societal level) and asthma,
we strongly concur with Lawrence that any
attempt to unravel associations must take a
multidisciplinary approach. 
Rosalind J. Wright
Channing Laboratory
Boston, Massachusetts
E-mail: rosalind.wright@
channing.harvard.edu
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a Kidney Cancer Cluster
Attributed to Trichloroethylene
Exposure
In a letter commenting on the analysis of
trichloroethylene (TCE) epidemiology by
Wartenberg et al. (1), Borak et al. (2) called
into question the statistical interpretation
of the key study by Henschler et al. (3) on
the grounds that the Henschler study,
although cast and analyzed as a cohort
study, was based on a previously recognized
cluster of kidney cancer cases. In reply,
Wartenberg and Reyner (4) stated that 
the results of Henschler et al. … were so extreme
(5 cases where 0.628 were expected) that the
probability of observing such a situation is less
than 5 × 10–5, under Poisson assumptions. In
other words, if there were no association, one
would have to search for 500,000 similar work-
places with comparable TCE exposures to find
such occurrence due to chance alone. 
In fact, a closer examination of the issue
shows that the result of Henschler et al. (3)
is not at all unexpected as a result of chance
alone when it is encountered as a cluster
that calls attention to itself after the fact.
Wartenberg and Reyner’s (4) approach to
this question is appropriate in principle—
comparing the cluster result against an artic-
ulated statistical null hypothesis—but it is
mistaken in execution. In the first place,
5 × 10–5 corresponds to 1 in 20,000, not 1
in 500,000. Second, for an expected num-
ber of 0.628, the correct Poisson probability
of observing an outcome as extreme as 5
cases is actually about 4.8 × 10–4, an order
of magnitude less unusual than Wartenberg
and Reyner state. Third, the calculation of
the number of workplaces needed for one
among them to have a randomly generated
apparent cluster does not acknowledge that
this is a matter of probability.
The probability 4.8 × 10–4 represents
the chance of finding 5 or more cases in a
single particular place where circumstances
lead to an expected number of cases of only
0.628. The probability that such an
extreme outcome would happen by chance
at least once among a large number, N, of
such places, all subject to the same chance
events, is given by 1 – (1 – 5 × 10–4)N; that
is, it is 1 minus the probability of observing
no instances of extreme outcomes in the
collected set of N places.
The probability that, by chance alone,
an apparently “extreme” outcome occurs in
at least one unspecified location goes up sur-
prisingly rapidly with the number of loca-
tions that are considered. In this particular
case, by chance alone there is a 5% proba-
bility that at least 1 of 106 locations would
show an outcome judged to have an a priori
probability < 4.8 × 10–4. The odds are even
(50% probability) that one would find at
least 1 instance of such an “extreme” out-
come among 1,431 places, and it takes only
6,184 places subject to the random effect to
be virtually assured (95% probability) that
at least 1 of them will show an outcome as
extreme as that observed by Henschler et al.
(3) in terms of calculated a priori probabili-
ty. These numbers are far less than the
500,000 workplaces that Wartenberg and
Reyner (4) cite as being necessary.
In practice, when evaluating an apparent
cluster, it is difficult to be precise about the
number, N, of places that comprise the uni-
verse of locations in which a cluster could
potentially be observed under the null
hypothesis of randomness. In interpreting the
study of Henschler et al. (3), one should not
confine consideration to workplaces with
trichloroethylene exposure because such
exposure is part of the after-the-fact associa-
tion with the particular outcome in the par-
ticular factory where (under the null hypoth-
esis of randomness) the unusual co-occur-
rence of five cases happened to be observed,
and such a random occurrence could have
happened in a quite different kind of work-
place. The appropriate N would seem to
include all workplaces in Germany (or in
Europe, or in the world) in which an appar-
ent cluster of kidney cancer cases could in
principle have been recognized. Given that
only just over 1,000 such places need exist
before one expects to encounter a random
occurrence of clustering of kidney cancer
cases as extreme as seen by Henschler et al.
(3), the observation of the particular cluster is
not at all unexpected by chance alone.
The magnitude of difference between a
priori and a posteriori probabilities is coun-
terintuitive because we tend to forget about
the “denominator”—the many places sub-
ject to the same random occurrences where
an unusual confluence of cases did not
occur and call attention to itself—but the
difference is demonstrable by calculation.
When considered properly, the weakness of
arguments based on clusters recognized
after the fact, and the dangers of faulty rea-
soning regarding them, are apparent. It is
for these reasons that epidemiologic studies
need to be designed and interpreted in
terms of a priori risks.
Lorenz Rhomberg
Gradient Corporation
Cambridge, Massachusetts
E-mail: lrhomber@GradientCorp.com
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Canadian Hot Weather
Health-Response Plan
In a recent issue of EHP, Smoyer-Tomic
and Rainham (1) reported increased mor-
tality among those older than 64 years of
age in Toronto, Ontario, Canada, when the
humidex ranged between 30 and 35°C. In
all probability, the rising humidex tempera-
tures would concurrently affect potency
and bioavailibility of therapeutics offered to
patients in clinical practice. 
Therapeutic agents require constant stor-
age in a controlled temperature range—from
a sub-zero temperature to either 2–8°C or
25–30°C. Inadvertent exposures to high
humidity and temperature would alter the
potency of the medicines. That was evident
during a field exercise in Nigeria when the
active ingredients in 48% of the common
therapeutics were outside the limits specified
by the British Pharmacopoeia (2). An identi-
cal scenario could not be ruled out in
Toronto or elsewhere. During the mid-
1990s in Toronto, vaccines were properly
refrigerated only in 47.5% of general and
pediatric practices. Furthermore, only 10%
of these practices kept a record of refrigera-
tor temperature, and in 33% of sites, the
temperature range was outside the recom-
mended range (3). A well-controlled tem-
perature and humidity in warehouses with
stocks of pharmaceuticals cannot guarantee
full potency of medicines, and the tempera-
ture and humidity in households are not
necessarily appropriate for all medications
and do not remain constant.
Prospective hot weather health-response
strategies will not be comprehensive unless
they address any cryptic loss in potency and
bioavailability of the therapeutic agents used
in households. Failures should be assessed in
the field. Simple assay formats that could
accomplish qualitative and quantitative
analysis of therapeutics in the clinical and
household setting should be standardized.
Recently, Green et al. (4) proposed a quick
and simple test that requires few chemicals
and no sophisticated equipment to identify
artesunate, an antimalarial drug, in the field.
Identical tests for frequently used medicines
would confirm the quality of medicines
consumed when humidex values exceed
30–35°C in Toronto or anywhere in the
world. Also, such a strategy would address
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warm-climate health susceptibility depen-
dent on age above 64 years (1). 
Subhash C. Arya
Centre for Logistical Research 
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Hot Weather and Therapeutic
Agents: Response to Arya
Our evaluation of hot weather health-
response strategies was geared toward esti-
mating and preventing excess deaths from
heat stress (1). The issues regarding storage
of therapeutic agents that Arya raises are
important ones, however. To expand on his
point, the effects of ambient weather condi-
tions should be broadened to include
health impacts associated with physiologic
heat sensitivity stemming from medication
use, medication-induced photosensitivity,
and pharmacokinetics, as well as storage (2).
Although there is little evidence that ambient
heat and humidity affect absorption and elimi-
nation of orally administered drugs, there is
evidence of pharmocokinetic interactions for
transdermally and subcutaneously adminis-
tered drugs, such as insulin and nitroglycerin
(3). Because medication use is most prevalent
in older populations, who are also at greatest
risk of heat stress, Arya’s points about including
therapeutics in hot weather health warnings
are important, particularly for the elderly. 
Heat indexes, like humidex (used in
Canada) and apparent temperature (used in
the United States) are more appropriate than
temperature alone for human health effects.
Although they can be useful in predicting
high-risk periods for medication-induced
weather and ultraviolet radiation sensitivity
and for pharmocokinetic changes, heat
indexes are not readily applicable to nonliv-
ing organisms. Thus we do not recommend
them for advisories about proper storage of
therapeutic agents. Most agents are effective
only within a range of temperature and
humidity values, which should be evaluated
separately rather than as a composite heat
index when considering proper storage con-
ditions. Nonetheless, hot weather health-
response information could address the
issues raised here and by Arya through wide
dissemination to health providers and phar-
maceutical suppliers and users.
Karen E. Smoyer-Tomic
University of Alberta
Edmonton, Alberta, Canada
E-mail: karen.tomic@ualberta.ca
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NEHA is proud to announce the 2002 Annual Educational Conference (AEC) and Exhibition. The AEC and Exhibition includes comprehen-
sive educational sessions on the following environmental health topics:
  Chemical and Bioterrorism Preparedness
  Food Safety and Protection
  Onsite Wastewater Systems 
  Indoor Air Quality
  Hazardous Materials and Waste
  Drinking Water Quality 
  Emerging Pathogens
  Vector Control and Zoonotic Diseases
Sign up by June 15, 2002 and you will receive the special full conference rate of $429 for members and $539 for non-members—a $70
savings off of the post June 15 rates! For more information on the NEHA AEC and Exhibition, please contact a NEHA Service Specialist at
303-756-9090, extension 0 or visit the NEHA Web site at www.neha.org/tracks.html.
Announcing the 2002 NEHA 
Annual Educational Conference and Exhibition!
Presented by the National Environmental Health Association (NEHA) 
June 30 - July 3, 2002 (Exhibit Dates: June 30 - July 1, 2002)
Minneapolis Hilton Hotel, Minneapolis, MN
“The information that is presented at the conference is
always useful and applicable in my normal, routine work—
but, in retrospect, it would have been hard to envision how
prophetic the information that we received would become
since September 11. At the local preparatory meetings in
which I have participated in the last few weeks, the knowl-
edge that I learned as a result of the conference has proved
invaluable. As always, NEHA is on the cutting edge.”
Brenda Clark, Food Program Specialist, Mississippi State
Department of Health, Corinth, MS